According to research presented at the International AIDS Society conference, Merck & Co."s Isentress [raltegravir] failed to reduce low-level reservoirs of HIV. A study was done on patients whose viral levels were almost undetectable for 6 months while using standard antivirals. Participants had a 12 week course of Isentress or placebo then a further 12 week course of an alternate therapy. No difference in low levels were detected using highly sensitive tests.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지